Endo International (NASDAQ:ENDP) (TSE:ENL) was downgraded by research analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Thursday.

A number of other equities research analysts also recently commented on the stock. Royal Bank of Canada upgraded shares of Endo International from a “sector perform” rating to an “outperform” rating and set a $26.00 price objective for the company in a research report on Monday, August 13th. Zacks Investment Research upgraded shares of Endo International from a “hold” rating to a “buy” rating and set a $18.00 price target for the company in a research report on Monday, September 24th. Goldman Sachs Group upgraded shares of Endo International from a “sell” rating to a “neutral” rating and lifted their price target for the company from $14.00 to $15.00 in a research report on Tuesday, September 11th. TheStreet upgraded shares of Endo International from a “d” rating to a “c-” rating in a research report on Monday, August 20th. Finally, BidaskClub downgraded shares of Endo International from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 8th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $14.97.

Shares of NASDAQ:ENDP opened at $13.49 on Thursday. The stock has a market capitalization of $3.59 billion, a P/E ratio of 3.51, a PEG ratio of 1.54 and a beta of 0.65. Endo International has a 52 week low of $5.27 and a 52 week high of $18.50.

Endo International (NASDAQ:ENDP) (TSE:ENL) last announced its quarterly earnings data on Thursday, November 8th. The company reported $0.71 EPS for the quarter, beating the Zacks’ consensus estimate of $0.59 by $0.12. The firm had revenue of $745.00 million during the quarter, compared to the consensus estimate of $694.93 million. Endo International had a negative net margin of 34.72% and a positive return on equity of 237.45%. The firm’s revenue was down 5.3% compared to the same quarter last year. During the same quarter last year, the firm earned $0.91 earnings per share. Equities analysts forecast that Endo International will post 2.68 EPS for the current year.

In other news, Director Roger H. Kimmel sold 26,074 shares of the firm’s stock in a transaction that occurred on Tuesday, August 14th. The shares were sold at an average price of $15.90, for a total transaction of $414,576.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.80% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of ENDP. Schroder Investment Management Group increased its stake in shares of Endo International by 78.1% during the 2nd quarter. Schroder Investment Management Group now owns 747,571 shares of the company’s stock worth $7,349,000 after purchasing an additional 327,775 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of Endo International by 13.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 2,446,852 shares of the company’s stock worth $23,074,000 after purchasing an additional 284,599 shares in the last quarter. Sivik Global Healthcare LLC purchased a new position in shares of Endo International during the 2nd quarter worth approximately $1,697,000. Arizona State Retirement System increased its stake in shares of Endo International by 115.7% during the 2nd quarter. Arizona State Retirement System now owns 293,200 shares of the company’s stock worth $2,765,000 after purchasing an additional 157,252 shares in the last quarter. Finally, Capital Growth Management LP purchased a new position in shares of Endo International during the 3rd quarter worth approximately $2,356,000. 98.43% of the stock is owned by institutional investors and hedge funds.

About Endo International

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.

Featured Story: How much money do you need to begin day trading?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.